Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Table 2

Angiographic and procedural characteristics of patients.

Characteristic	CDDP; ( = 115)	Control; ( = 114)	value
Interval from admission to PCI (days)	6.3 ± 1.5	6.5 ± 1.1	0.887
Coronary vessel treated
Left main	19 (16.5%)	15 (13.2%)	0.474
Left anterior descending	57 (49.6%)	68 (59.7%)	0.125
Left circumflex	25 (21.7%)	20 (17.5%)	0.496
Right	41 (35.7%)	32 (28.1%)	0.078
Type of procedure
Balloon only ()	6 (5.2%)	7 (6.1%)	0.763
Stent ()	109 (94.8%)	107 (93.9%)	0.763
Stents used per patient	2.25 ± 1.2	2.00 ± 0.8	0.750
Total stent length (mm)	25.3 ± 5.1	24.0 ± 8.5	0.827
Preprocedural antithrombotic therapy
Glycoprotein IIb/IIIa inhibitors	83 (72.2%)	79 (69.3%)	0.632
Unfractionated heparin	110 (95.7%)	107 (93.9%)	0.543
Bivalirudin	5 (4.3%)	7 (6.1%)	0.543
Total mean contrast volume (mL)	163.3 ± 35.1	183.3 ± 27.2	0.754